Clinical trialNACompleted
Combination of SBRT With Sequential S-1 for Treating Locally Advanced Pancreatic Cancer
Stereotactic Body Radiation Therapy With Sequential S-1 for Patients With Locally Advanced Pancreatic Cancer and Poor Medical Conditions --a Phase II Clinical Trial
- Outcome
- Outcome unknown
- Phase
- NA
- Status
- Completed
- Study type
- Interventional
- Start
- February 2016
- Expected end
- May 2020
- Enrollment
- 63 participants
- Sites
- 1
- Primary outcomes
- One-year Overall Survival Rate
- Sponsor
- Other
- Results posted
- 2020-07-17
- Last update
- 19 October 2020
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 7
- Builds on itStereotactic body radiation therapy with sequential S-1 for patients with locally advanced pancreatic cancer and poor p… DOI 10.1016/j.radonc.2021.07.009↗
- Builds on itSafety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 … DOI 10.1136/bmjopen-2016-013220↗
- BackgroundS-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancre… DOI 10.1634/theoncologist.2014-0223↗
- BackgroundStereotactic body radiation therapy in pancreatic cancer: the new frontier. DOI 10.1586/14737140.2014.952286↗
- BackgroundRandomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced a… DOI 10.1200/jco.2012.43.3680↗
- BackgroundEmerging role of stereotactic body radiotherapy in the treatment of pancreatic cancer. DOI 10.1586/era.13.19↗
- BackgroundPhase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. DOI 10.1007/s00280-010-1311-3↗